- Home
- PSNYW vs DCTH Comparison
PSNYW vs DCTH Comparison
Compare PSNYW & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNYW
- DCTH
- Stock Information
- Founded
- PSNYW N/A
- DCTH 1988
- Country
- PSNYW Sweden
- DCTH United States
- Employees
- PSNYW 2515
- DCTH N/A
- Industry
- PSNYW Auto Manufacturing
- DCTH Medical/Dental Instruments
- Sector
- PSNYW Consumer Discretionary
- DCTH Health Care
- Exchange
- PSNYW Nasdaq
- DCTH Nasdaq
- Market Cap
- PSNYW 324.1M
- DCTH 305.2M
- IPO Year
- PSNYW N/A
- DCTH N/A
- Fundamental
- Price
- PSNYW $0.14
- DCTH $9.76
- Analyst Decision
- PSNYW
- DCTH Strong Buy
- Analyst Count
- PSNYW 0
- DCTH 4
- Target Price
- PSNYW N/A
- DCTH $21.50
- AVG Volume (30 Days)
- PSNYW N/A
- DCTH 459.4K
- Earning Date
- PSNYW N/A
- DCTH 11-08-2024
- Dividend Yield
- PSNYW N/A
- DCTH N/A
- EPS Growth
- PSNYW N/A
- DCTH N/A
- EPS
- PSNYW N/A
- DCTH N/A
- Revenue
- PSNYW N/A
- DCTH $22,644,000.00
- Revenue This Year
- PSNYW N/A
- DCTH $1,562.76
- Revenue Next Year
- PSNYW N/A
- DCTH $117.72
- P/E Ratio
- PSNYW N/A
- DCTH N/A
- Revenue Growth
- PSNYW N/A
- DCTH 945.91
- 52 Week Low
- PSNYW N/A
- DCTH $2.60
- 52 Week High
- PSNYW N/A
- DCTH $12.88
- Technical
- Relative Strength Index (RSI)
- PSNYW 27.25
- DCTH 47.05
- Support Level
- PSNYW $0.12
- DCTH $9.50
- Resistance Level
- PSNYW $0.24
- DCTH $10.04
- Average True Range (ATR)
- PSNYW 0.02
- DCTH 0.66
- MACD
- PSNYW -0.01
- DCTH -0.10
- Stochastic Oscillator
- PSNYW 11.72
- DCTH 22.19
About PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market-leading standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from USA.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.